Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Dec;93(12):2087-9.
doi: 10.1007/s00277-014-2104-2. Epub 2014 May 27.

Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib

V Vergote  1 , D Dierickx, A Janssens, G Verhoef, T Tousseyn, P Vandenberghe, P Wolter, M Delforge
Affiliations
Case Reports

Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib

V Vergote et al. Ann Hematol. 2014 Dec.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • Braf mutation in interdigitating dendritic cell sarcoma: a case report and review of the literature.
    Di Liso E, Pennelli N, Lodovichetti G, Ghiotto C, Dei Tos AP, Conte P, Bonanno L. Di Liso E, et al. Cancer Biol Ther. 2015;16(8):1128-35. doi: 10.1080/15384047.2015.1057359. Cancer Biol Ther. 2015. PMID: 26047060 Free PMC article. Review.
  • Recent advances in understanding and managing hairy cell leukemia.
    Roider T, Falini B, Dietrich S. Roider T, et al. F1000Res. 2018 Apr 27;7:F1000 Faculty Rev-509. doi: 10.12688/f1000research.13265.1. eCollection 2018. F1000Res. 2018. PMID: 29770206 Free PMC article. Review.
  • Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
    Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B. Grever MR, et al. Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30. Blood. 2017. PMID: 27903528 Free PMC article.
  • Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
    Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS. Tiacci E, et al. N Engl J Med. 2015 Oct 29;373(18):1733-47. doi: 10.1056/NEJMoa1506583. Epub 2015 Sep 9. N Engl J Med. 2015. PMID: 26352686 Free PMC article. Clinical Trial.
  • How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
    Falini B, De Carolis L, Tiacci E. Falini B, et al. Blood. 2022 Apr 14;139(15):2294-2305. doi: 10.1182/blood.2021013502. Blood. 2022. PMID: 35143639 Free PMC article.
See all "Cited by" articles

MeSH terms